Pilot study of zidovudine–lamivudine combination therapy in vertically HIV-infected antiretroviral-naive children

Horneff, Gerd; Adams, Ortwin; Wahn, V.

doi:10.1097/00002030-199805000-00010

Cited by 15 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[2][3][4][5][6][7][8][9][10][11][12] Alternatively, monotherapy with the protease inhibitor indinavir resulted in marked, but only temporary, reductions of viral load in antiretroviral therapy naive and experienced adult patients, as well as in children. 13,14 Several small observational and retrospective studies reported that triple therapy including a protease inhibitor may be as effective in pre-treated HIV-1-infected children as in adults, as shown by a decrease of viral load and an increase of CD4 cell count similar to those in adults who had previously received antiretroviral therapy.…”

Section: Van Rossum Et Almentioning

confidence: 99%

Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection

Viganò¹,

Dally²,

Bricalli³

et al. 1999

The Journal of Pediatrics

View full text Add to dashboard Cite

Objective: To evaluate the clinical, immunologic, and virologic response to indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 (HIV-1) infection.Study design: Twenty-eight HIV-1-infected children (3 months to 16 years of age) with or without prior treatment with reverse-transeriptase inhibitors and a HIV-1 RNA >5000 copies/mL and/or a CD4 cell count less than the lower limit of the age-specific reference value were treated with indinavir, zidovudine, and lamivudine. Pharmacokinetics of indinavir were determined in each child.Results: The combination treatment was well tolerated in the majority of patients. Clinical improvement was seen in all patients. After 6 months of therapy, 70% of the patients had an HIV-1 RNA load below 500 copies/mL, whereas 48% of the children had a viral load below 40 copies/mL. Relative CD4 cell counts in relation to the lower limit of the age-specific reference value increased significantly from a median value of 79% at baseline to 106% after 6 months of therapy. The doses of indinavir necessary to achieve area under the curve values comparable to adult values varied from 1250 mg/m2/d to 2450 mg/m2/d. Conclusions: Highly active antiretroviral therapy consisting of indinavir, zidovudine, and lamivudine in children reduced HIV-1 RNA to less than 500 copies/mL in 70% of the children within 6 months. Improved CD4 cell counts were observed in most patients, as was a better clinical condition (no invasive or opportunistic infections, increased weight gain). Side effects of the triple therapy were mild. Highly active antiretroviral therapy can be used as successfully in children as in adults. (J Pediatr 2000;136:780-8)

show abstract

Section: Van Rossum Et Almentioning

confidence: 99%

Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection

Viganò¹,

Dally²,

Bricalli³

et al. 1999

The Journal of Pediatrics

View full text Add to dashboard Cite

show abstract

“…Recent studies in children with HIV infection treated with a combination of 2 reverse-transcriptase inhibitors showed superior results as compared with monotherapy. [2][3][4][5][6][7][8][9][10][11][12] Alternatively, monotherapy with the protease inhibitor indinavir resulted in marked, but only temporary, reductions of viral load in antiretroviral therapy naive and experienced adult patients, as well as in children. 13,14 Several small observational and retrospective studies reported that triple therapy including a protease inhibitor may be as effective in pre-treated HIV-1-infected children as in adults, as shown by a decrease of viral load and an increase of CD4 cell count similar to those in adults who had previously received antiretroviral therapy.…”

mentioning

confidence: 99%

Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: A multicenter study in The Netherlands

Rossum

Niesters

Geelen

et al. 2000

The Journal of Pediatrics

View full text Add to dashboard Cite

“…A terapia combinada de ZDV/3TC é promissora pois vírus resistentes a ZDV são fenotipicamente sensíveis à lamivudina pela mutação do resíduo 184. Além disso, é pequena ou inexistente a coresistência entre ambos (Horneff et al, 1998). Recentes estudos avaliaram as propriedades farmacocinéticas e farmacodinâmicas dos agentes anti-retrovirais.…”

Section: Indicações Terapêuticas E Doseunclassified

Atividade anti-retroviral e propriedades farmacocinéticas da associação entre lamivudina e zidovudina

Souza¹,

Storpirtis²

2004

Rev. Bras. Cienc. Farm.

View full text Add to dashboard Cite

Pilot study of zidovudine–lamivudine combination therapy in vertically HIV-infected antiretroviral-naive children

Abstract: This pilot study demonstrates the feasibility of zidovudine-lamivudine combination in children not previously exposed to antiretroviral drugs. This promising combination should therefore be evaluated in larger trials.

Cited by 15 publications

References 22 publications

Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection

Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection

Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: A multicenter study in The Netherlands

Atividade anti-retroviral e propriedades farmacocinéticas da associação entre lamivudina e zidovudina

Contact Info

Product

Resources

About